8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
West Pharmaceutical raises 2026 sales and adjusted EPS guidance after strong Q3
Filed with the SEC on · Summarized by InvestorsBot
West Pharmaceutical reported third-quarter 2026 net sales of $874.5 million, up 8.7% year over year, while adjusted diluted EPS rose 35.7% to $2.66; organic sales increased 11.9%, led by High-Value Product Components. The company raised full-year 2026 net sales guidance to $3.41 billion-$3.42 billion and adjusted diluted EPS guidance to $9.38-$9.48, while lowering capital-spending guidance to $215 million-$220 million; it also repurchased $231 million of stock in the quarter and $685 million year to date.